Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Dynamics of Radiomic Features Following Bridging Therapy Determine CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcome

Blood (2023) 142 (Supplement 1): 2123.

https://doi.org/10.1182/blood-2023-187763

Published: 2023

Journal Articles

Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study

Luke Maese, Mignon L. Loh, Mi Rim Choi, Tong Lin, Etsuko Aoki, Michelle Zanette, Shirali Agarwal, Robert Iannone, Jeffrey A. Silverman, Lewis B. Silverman, Elizabeth A. Raetz, Rachel E. Rau

Blood (2023) 141 (7): 704–712.

https://doi.org/10.1182/blood.2022016923

Published: 2023

Includes: Supplemental data

Journal Articles

Efficacy, Safety, and Population Pharmacokinetic Modeling of Intravenous Recombinant Erwinia Asparaginase (JZP458) in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma: Results from Study AALL1931

Luke Maese, Mignon L. Loh, Mi Rim Choi, Tong Lin, Etsuko Aoki, Shirali Agarwal, Xiaotian Wu, Robert Iannone, Jeffrey A. Silverman, Lewis B. Silverman, Elizabeth A. Raetz, Rachel E. Rau

Blood (2022) 140 (Supplement 1): 8969–8970.

https://doi.org/10.1182/blood-2022-160192

Published: 2022

Journal Articles

Initial Results from a Phase 2/3 Study of Recombinant Erwinia Asparaginase (JZP458) in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Who Are Allergic/Hypersensitive to E. coli-Derived Asparaginases

Luke Maese, Mignon L. Loh, Tong Lin, Etsuko Aoki, Michelle Zanette, Shirali Agarwal, Jeffrey A. Silverman, Mi Rim Choi, Lewis B. Silverman, Elizabeth A. Raetz, Rachel E. Rau

Blood (2021) 138 (Supplement 1): 2307.

https://doi.org/10.1182/blood-2021-147023

Published: 2021

Journal Articles

Five-Year Experience Using Bridging Radiotherapy Prior to Chimeric Antigen Receptor (CAR) T-Cell Therapies for B-Cell Malignancies at Memorial Sloan Kettering Cancer Center

Blood (2021) 138 (Supplement 1): 2507.

https://doi.org/10.1182/blood-2021-151179

Published: 2021

Journal Articles

Lesion Characteristics and Patterns of Failure in Diffuse Large B Cell Lymphoma Patients Treated with Bridging Radiotherapy Prior to Chimeric Antigen Receptor T Cell Therapy

Blood (2021) 138 (Supplement 1): 1429.

https://doi.org/10.1182/blood-2021-149702

Published: 2021

Journal Articles

Hedgehog Pathway Mutations Drive Oncogenic Transformation in High-Risk T-Cell Acute Lymphoblastic Leukemia

Melissa A. Burns, MD, Zi Wei Liao, Gayle P. Pouliot, MD PhD, Kristen E. Stevenson, MS, Donna S. Neuberg, ScD, Aaron R. Thorner, PhD, Matthew D. Ducar, MS, Emily A. Silverman, Stephen P. Hunger, MD, Mignon L. Loh, MD, Stuart S. Winter, MD, Kimberly P. Dunsmore, MD, Brent Wood, MDPhD, Meenakshi Devidas, PhD, Marian H. Harris, MD PhD, Lewis B. Silverman, MD, Stephen E. Sallan, MD, Alejandro Gutierrez, MD

Blood (2017) 130 (Supplement 1): 367.

https://doi.org/10.1182/blood.V130.Suppl_1.367.367

Published: 2017

Journal Articles

Growth Disturbances in Pediatric Patients Receiving Long-Term Tyrosine Kinase Inhibitor Therapy

Himalee Sabnis, MDMS, Caroline Keenum, MD, Rebecca Williamson Lewis, MPH, Emily A. Silverman, Briana Patterson, MD, Karen E. Effinger, MD, John Bergsagel, MD, Ann Mertens, PhD, Sharon M. Castellino, MD MSc

Blood (2017) 130 (Supplement 1): 3425.

https://doi.org/10.1182/blood.V130.Suppl_1.3425.3425

Published: 2017

Journal Articles

Hemopoietic Progenitor Cells from the Bone Marrow of Serpinb3A-/- Mice Are Radioresistant

Stephanie Thermozier, Michael W. Epperly, PhD, Darcy Franicola, Xichen Zhang, Renee Fisher, Donna Shields, Hong Wang, John A. Willis, Cliff Luke, Gary A. Silverman, Joel S. Greenberger, MD

Blood (2016) 128 (22): 2680.

https://doi.org/10.1182/blood.V128.22.2680.2680

Published: 2016

Journal Articles

High-Dose Vincristine Sulfate Liposome Injection (Marqibo ® ) Is Not Associated With Clinically Meaningful Hematologic Toxicity

Olivia R. Deitcher, John Glaspy, MD, Rene Gonzalez, MD, Takami Sato, Agop Bedikian, MD, Karen Segarini, Jeffrey A. Silverman, Ph.D., Steven R. Deitcher, MD

Blood (2013) 122 (21): 2676.

https://doi.org/10.1182/blood.V122.21.2676.2676

Published: 2013

Journal Articles

Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo ® ) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin’s Lymphomas

Fredrick B. Hagemeister, MD, Maria Alma Rodriguez, MD, Steven R. Deitcher, MD, Anas Younes, MD, Luis Fayad, MD, Andre Goy, MD, Nam H. Dang, MD, PhD, A Forman, MD, Peter McLaughlin, MD, Barbara Pro, MD, Jorge Enrique Romaguera, Felipe Samaniego, MD, Jeffrey A. Silverman, Ph.D., Andreas H. Sarris, MD, PhD, Fernando Cabanillas, MD

Blood (2013) 122 (21): 3033.

https://doi.org/10.1182/blood.V122.21.3033.3033

Published: 2013

Journal Articles

Vincristine Sulfate Liposome Injection (Marqibo ® ) and Rituximab For Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma Or Mantle Cell Lymphoma In Need Of Palliative Therapy

Lawrence D. Kaplan, MD, Steven R. Deitcher, MD, Jeffrey A. Silverman, Ph.D., Gareth J Morgan, MD, PhD

Blood (2013) 122 (21): 4355.

https://doi.org/10.1182/blood.V122.21.4355.4355

Published: 2013

Journal Articles

Neurotoxicity Profile of Vincristine Sulfate Liposome Injection (VSLI, Marqibo®) Monotherapy in Adults with Relapsed Acute Lymphoblastic Leukemia and Universal Prior Standard Vincristine Exposure

Steven R. Deitcher, MD, Jeffrey A. Silverman, Ph.D.

Blood (2012) 120 (21): 3568.

https://doi.org/10.1182/blood.V120.21.3568.3568

Published: 2012

Journal Articles

Minimal Residual Disease in Adults with Advanced Relapsed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Treated with Marqibo ® (vinCRIStine sulfate LIPOSOME injection)

Olivia R. Deitcher, Stuart L. Goldberg, MD, Wendy Stock, MD, Gary J. Schiller, MD, John Lister, MD, Jeffrey A. Silverman, Ph.D., Steven R. Deitcher, MD, Susan O'Brien, M.D.

Blood (2012) 120 (21): 4805.

https://doi.org/10.1182/blood.V120.21.4805.4805

Published: 2012

Journal Articles

Design of the Hallmarq Trial, a Phase 3 Study of Vincristine Sulfate Liposome Injection (VSLI, Marqibo®) in Adults with Newly Diagnosed, Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia

Steven R. Deitcher, MD, Jeffrey A. Silverman, Ph.D.

Blood (2012) 120 (21): 4300.

https://doi.org/10.1182/blood.V120.21.4300.4300

Published: 2012

Journal Articles

Vincristine Sulfate Liposome Injection (VSLI, Marqibo®) Facilitates Increased Delivery of Vincristine Sulfate to Target Cancer Tissues.

Jeffrey A. Silverman, Ph.D., Steven R. Deitcher, MD

Blood (2012) 120 (21): 2457.

https://doi.org/10.1182/blood.V120.21.2457.2457

Published: 2012

Journal Articles

Vincristine Sulfate Liposomes Injection (Marqibo ® ) Facilitates Durable Remissions and Potentially Curative Hematopoietic Stem Cell Transplantation in Adults with Advanced, Relapsed and/or Refractory Acute Lymphoblastic Leukemia

Gary J. Schiller, MD, John Lister, MD, Leonard T. Heffner, MD, Stuart L. Goldberg, MD, Lloyd E. Damon, MD, Jeffrey A. Silverman, Ph.D., Steven R. Deitcher, MD

Blood (2011) 118 (21): 4235.

https://doi.org/10.1182/blood.V118.21.4235.4235

Published: 2011

Journal Articles

Marqibo ® (vincristine sulfate liposomes injection; VSLI) Optimizes the Dosing, Delivery, and Pharmacokinetic (PK) Profile of Vincristine Sulfate (VCR) In Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL)

Jeffrey A Silverman, PhD, Walter E. Aulitzky, MD, John Lister, MD, Lori Maness, M.D., Gary J Schiller, MD, Karen Seiter, MD, Scott Smith, MD, PhD, FACP, Wendy Stock, MD, Dina Ben Yehuda, Steven R. Deitcher, MD

Blood (2010) 116 (21): 2142.

https://doi.org/10.1182/blood.V116.21.2142.2142

Published: 2010

Journal Articles

Urokinase-type plasminogen activator is a preferred substrate of the human epithelium serine protease tryptase ϵ/PRSS22

Shinsuke Yasuda, Nasa Morokawa, G. William Wong, Andrea Rossi, Mallur S. Madhusudhan, Andrej Šali, Yuko S. Askew, Roberto Adachi, Gary A. Silverman, Steven A. Krilis, Richard L. Stevens

Blood (2005) 105 (10): 3893–3901.

https://doi.org/10.1182/blood-2003-10-3501

Published: 2005

Journal Articles

Prothymosin alpha gene expression correlates with proliferation, not differentiation, of HL-60 cells

MR Smith, A al-Katib, R Mohammad, A Silverman, P Szabo, S Khilnani, W Kohler, R Nath, MG Mutchnick

Blood (1993) 82 (4): 1127–1132.

https://doi.org/10.1182/blood.V82.4.1127.1127

Published: 1993

NARROW

Dynamics of Radiomic Features Following Bridging Therapy Determine CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcome

Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study

Efficacy, Safety, and Population Pharmacokinetic Modeling of Intravenous Recombinant Erwinia Asparaginase (JZP458) in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma: Results from Study AALL1931

Initial Results from a Phase 2/3 Study of Recombinant Erwinia Asparaginase (JZP458) in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Who Are Allergic/Hypersensitive to E. coli-Derived Asparaginases

Five-Year Experience Using Bridging Radiotherapy Prior to Chimeric Antigen Receptor (CAR) T-Cell Therapies for B-Cell Malignancies at Memorial Sloan Kettering Cancer Center

Lesion Characteristics and Patterns of Failure in Diffuse Large B Cell Lymphoma Patients Treated with Bridging Radiotherapy Prior to Chimeric Antigen Receptor T Cell Therapy

Hedgehog Pathway Mutations Drive Oncogenic Transformation in High-Risk T-Cell Acute Lymphoblastic Leukemia

Growth Disturbances in Pediatric Patients Receiving Long-Term Tyrosine Kinase Inhibitor Therapy

Hemopoietic Progenitor Cells from the Bone Marrow of Serpinb3A-/- Mice Are Radioresistant

High-Dose Vincristine Sulfate Liposome Injection (Marqibo ® ) Is Not Associated With Clinically Meaningful Hematologic Toxicity

Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo ® ) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin’s Lymphomas

Vincristine Sulfate Liposome Injection (Marqibo ® ) and Rituximab For Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma Or Mantle Cell Lymphoma In Need Of Palliative Therapy

Neurotoxicity Profile of Vincristine Sulfate Liposome Injection (VSLI, Marqibo®) Monotherapy in Adults with Relapsed Acute Lymphoblastic Leukemia and Universal Prior Standard Vincristine Exposure

Minimal Residual Disease in Adults with Advanced Relapsed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Treated with Marqibo ® (vinCRIStine sulfate LIPOSOME injection)

Design of the Hallmarq Trial, a Phase 3 Study of Vincristine Sulfate Liposome Injection (VSLI, Marqibo®) in Adults with Newly Diagnosed, Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia

Vincristine Sulfate Liposome Injection (VSLI, Marqibo®) Facilitates Increased Delivery of Vincristine Sulfate to Target Cancer Tissues.

Vincristine Sulfate Liposomes Injection (Marqibo ® ) Facilitates Durable Remissions and Potentially Curative Hematopoietic Stem Cell Transplantation in Adults with Advanced, Relapsed and/or Refractory Acute Lymphoblastic Leukemia

Marqibo ® (vincristine sulfate liposomes injection; VSLI) Optimizes the Dosing, Delivery, and Pharmacokinetic (PK) Profile of Vincristine Sulfate (VCR) In Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL)

Urokinase-type plasminogen activator is a preferred substrate of the human epithelium serine protease tryptase ϵ/PRSS22

Prothymosin alpha gene expression correlates with proliferation, not differentiation, of HL-60 cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only